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Background: Toxoplasma gondii possesses proteins that can modulate host immune responses. TgMIF is a homologue of
mammalian macrophage migration inhibitory factor.
Results: TgMIF possesses tautomerase but not oxidoreductase activity. It can stimulate ERK MAPK and IL-8 production.
Conclusion: TgMIF is capable of modulating host molecules.
Significance: The study identifies immunomodulatory activity of TgMIF consistent with a role for sustaining parasite survival.
Macrophagemigration inhibitory factor (MIF) is a proinflam-
matory molecule in mammals that, unusually for a cytokine,
exhibits tautomerase and oxidoreductase enzymatic activities.
Homologues of this well conserved protein are found within
diverse phyla including a number of parasitic organisms.
Herein, we produced recombinant histidine-tagged Toxo-
plasma gondii MIF (TgMIF), a 12-kDa protein that lacks oxi-
doreductase activity but exhibits tautomerase activity with a
specific activity of 19.3 mol/min/mg that cannot be inhibited
by the human MIF inhibitor ISO-1. The crystal structure of the
TgMIF homotrimer has been determined to 1.82 A˚, and
although it has close structural homology with mammalian
MIFs, it has critical differences in the tautomerase active site
that account for the different inhibitor sensitivity.We also dem-
onstrate that TgMIF can elicit IL-8 production from human
peripheral blood mononuclear cells while also activating ERK
MAPKpathways inmurine bonemarrow-derivedmacrophages.
TgMIF may therefore play an immunomodulatory role during
T. gondii infection in mammals.
Toxoplasma gondii is an obligate intracellular protozoanpar-
asite of significant economical and public health importance.
Infection with T. gondii is common, and it is estimated that
30% of theworld’s population is chronically infectedwith this
parasite. Typically, infection withT. gondii results in the induc-
tion of a classical type 1 response with the production of proin-
flammatory cytokines such as IFN- by natural killer cells andT
cells controlling acute infection characterized by the rapidly
dividing tachyzoite (1, 2). This response is not only essential for
host survival, but it also creates an environment that is favor-
able for maintaining parasite survival via the establishment of a
chronic latent infection characterized by a stage switch from
tachyzoite to slow dividing bradyzoite (3). Overproduction of
proinflammatory mediators can result in severe pathology; and
therefore, the induction of regulatorymediators such as IL-10 is
necessary to limit immune pathology during the course of
infection (4). The parasite plays a significant direct role in influ-
encing disease outcome, and recent studies have demonstrated
the ability of T. gondii to modulate host immune responses via
the activity of a number of parasite-specific proteins including
cyclophilin-18 and heat shock protein 70 (for reviews, see Refs.
5–7).
MIF2 is an ancient proinflammatory mammalian cytokine
that has been shown to participate in both innate and adaptive
immune responses (for reviews, see Refs. 8–10). It is highly
conserved in mammalian species with 86% amino acid
sequence identity among MIF in cat, mouse, and humans. The
proinflammatory activity of MIF has been implicated in a
diverse range of biological processes including activation of
ERK MAPK pathways in fibroblasts (11) and inhibition of the
anti-inflammatory actions of glucocorticoids (12).MIF has also
been shown to induce production of proinflammatory media-
tors such as TNF-, IL-8, and IL-17 (12–14) while maintaining
macrophage proinflammatory function by inhibiting p53-de-
pendent apoptosis of macrophages (15). Despite a clear role for
MIF as a proinflammatory mediator, it has also been suggested
that MIF may mediate anti-inflammatory activities via binding
Jab-1 and preventing AP-1 proinflammatory gene expression
(16). Significantly, homologues of MIF have been described in
many parasitic species including Plasmodium, Leishmania,
Brugia, Clostridium, and Eimeria, and it has been implied that
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these proteins facilitate the manipulation of the host immune
response during infection (17–21).
Herein, we report the biochemical and immunological char-
acterization of a homologue of MIF in T. gondii, TgMIF, for
which the crystal structure has been solved to 1.82-Å resolu-
tion. Furthermore, we have shown that TgMIF is a biochemi-
cally active protein that is capable of inducing IL-8 production
from human peripheral blood mononuclear cells (PBMCs)
while also activating ERK MAPK pathways in murine bone
marrow-derived macrophages. The existence of TgMIF may
facilitate parasitism in the definitive (Felidae), intermediate
(Mus musculus), and incidental (Homo sapiens) hosts.
EXPERIMENTAL PROCEDURES
Alignments—MIF sequences were retrieved from NCBI.
Sequence alignments were performed using Tcoffee, and
ESpript was then used to assemble Fig. 1.
Cloning, Expression, and Purification of C-terminal His-
tagged TgMIF—TgMIF was amplified from cDNA of the RH
strain using primers that had been specifically designed to
include NdeI and XhoI restriction sites (underlined) in the
forward and reverse primers, respectively, for cloning into vec-
tor pET21a. Primer sequences were as follows: forward
primer, 5-GGGGCATATGCCCAAGTGCATGATCTTTT-
GCC-3; and reverse primer, 5-GGGGCTCGAGGCCGAAA-
GTTCGGTCGCCCATGGC-3. The reverse primer was
designed to omit the stop codon and allow translation of the
C-terminal His tag on the pET21a vector. The TgMIF ORF
was amplified fromT. gondii (RH strain) cDNAusing aTaq and
Tgo DNA polymerase as part of a high fidelity PCR system
(Roche Applied Science). The 351-bp TgMIF ORF DNA prod-
uct was subsequently ligated into expression vector pET21a
(Novagen). Escherichia coli BL21 competent cells (Rosetta
strain) were transformed, and expression was induced by the
addition of 1mM isopropyl 1-thio--galactopyranoside at 30 °C
overnight. Cells were then lysed by sonication and the addition
of lysozyme (1 g/ml). Recombinant proteins were purified
usingNi2-nitrilotriacetic acid columns (Qiagen), elutedwith 1
M imidazole, and stored in a Tris-HCl buffer, pH 8 at6mg/ml
at 80 °C. For biological assays, endotoxin was removed from
protein samples using the ProteoSpin EndotoxinRemovalMaxi
kit (Novagen), and endotoxin levels were then quantified using
the QCL-1000 chromogenic Limulus amebocyte lysate end
point assay (Cambrex).
Crystallization—Crystals were grown by the hanging drop,
vapor diffusion method in 24-well Linbro plates. Crystals of
TgMIF grew at 277 K over a well solution containing 1.82 M
ammonium sulfate and 100 mM Tris, pH 6.5. The drop con-
tained 2 l of protein solution at 15 mg/ml in 50 mM Tris, pH
7.5 plus 2 l of well solution. Prior to data collection, crystals
were briefly immersed in a cryoprotectant solution containing
20% (v/v) glycerol plus well solution and then flash frozen in
liquid nitrogen.
X-rayData Collection and Structure Determination—All dif-
fraction data were collected at 100 K on beam-line I03 at the
Diamond Light Source (Oxfordshire, UK), indexed with
iMosflm, and merged and scaled with SCALA (22). For molec-
ular replacement, a homology model of the TgMIF structure
was generated using the SwissModel server and used as the
search model in PHASER (22). Structure building and refine-
ment was performed using Coot (23) and Refmac, respectively.
Data collection and refinement statistics are shown in Table 1.
The structure has beendeposited in theResearchCollaboratory
for Structural Bioinformatics Protein Data Bank under acces-
sion code 4DH4.
Enzyme Assays—Tautomerase assays were performed as
described previously (24). Tautomerase activity was measured
at 37 °C by the addition of 48 l of L-DOPA methyl ester (10
mM) ( 3700M1 cm1) to 32l of sodiumperiodate (20mM)
to which an equal volume of sodium phosphate buffer (10 mM,
pH 6.2) with 1 mM EDTA was added. To start the reaction, 80
g ofTgMIF and0.5g of humanMIF (HsMIF) (R&DSystems)
were added, and tautomerization of L-dopachrome methyl
ester was then measured at 474 nm. The inhibitory effect of
(S,R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid
(ISO-1) (Sigma) was determined by the preincubation of 80 g
of TgMIF and 0.5 g of HsMIF with 10 M ISO-1 for 30 min
prior to adding it to the substrate.
Culture of Human Peripheral Blood Mononuclear Cells—
Human PBMCs were isolated from freshly drawn blood using
Histopaque (Sigma-Aldrich). Isolated mononuclear cells were
seeded to 96-well plates at 5  106 cells/ml in RPMI 1640
medium containing 10%heat-inactivated fetal calf serum, 2mM
L-glutamine, 100 units/ml penicillin, and 100g/ml streptomy-
cin and incubated at 37 °C in 5% CO2. Cells were stimulated
with increasing concentrations of endotoxin-free TgMIF
(1–1000 ng/ml) for 24 h followingwhich cell supernatants were
collected for analysis by ELISA.
IL-8 Assay—To detect IL-8 in cell supernatants, 96-well
plates were coated with purified mouse anti-human IL-8
(Pharmingen) at 2g/ml in PBS, pH 9 and incubated overnight
at 4 °C. Following the addition of supernatants to wells, recom-
binant human IL-8 was also added to corresponding wells in
doubling dilutions ranging from 20 ng/ml to 387.5 pg/ml. Bioti-
nylated anti-human IL-8 (Pharmingen) was added to each well
at 1 g/ml before the addition of streptavidin-alkaline phos-
phate (Pharmingen) diluted 1:2000. Finally, p-nitrophenyl
phosphate (Sigma) at 1 mg/ml in glycine buffer was added, and
absorbances were recorded at 450 nm. All assays were carried
out in triplicate.
Isolation of Macrophages from Bone Marrow Stem Cells and
Sample Preparation—Femurs were removed from male BALB/
c mice and flushed using a 25-gauge needle with medium con-
sisting of 30% L cell-conditioned supernatant, 20% heat-inacti-
vated fetal calf serum, 2 mM L-glutamine, 100 units/ml penicil-
lin, and 100g/ml streptomycin inDulbecco’smodified Eagle’s
medium supplemented with sodium pyruvate, glucose, and
pyridoxine hydrochloride (Invitrogen). Flushed bone marrow
stem cells were passed through a 21-gauge needle before being
split between Petri dishes and incubated at 37 °C in 5% CO2.
Cultures were then supplemented with media on days 3 and 7.
Confluent macrophages were harvested and washed on day 10
and seeded at 1 106/ml in RPMI 1640medium supplemented
with 10% heat-inactivated fetal calf serum, 2 mM L-glutamine,
100 units/ml penicillin, and 100 g/ml streptomycin. Macro-
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phageswere incubated at 37 °C in 5%CO2 throughout the dura-
tion of the experiment.
Cells were stimulated with concentrations of endotoxin-free
TgMIF ranging from 1 to 1000 ng/ml over a 24-h period. Con-
trol cells were stimulated with 1 ng/ml HsMIF for 24 h before
samples were collected. To collect samples, cells were washed
in PBS and harvested by agitation in 150 l of sample buffer
after which samples were boiled to denature proteins.
ERK MAPK Western Blot—Stimulated macrophage samples
were resolved by 14% SDS-PAGE. Proteins were first resolved
in a polyacrylamide gel and then transferred to a nitrocellulose
membrane (AmershamBiosciences) using theNovexXcell Blot
Module (Invitrogen) at 30 V for 90 min. The membrane was
blocked for 2 h with a blocking buffer containing 10% FCS in
PBS after which themembrane was incubated overnight at 4 °C
in the blocking buffer containing the mouse anti-ERK antibody
(1:7500 dilution) (Santa Cruz Biotechnology). The membrane
was washed for 90min, changing the wash buffer (PBS contain-
ing 0.05% Tween 20) every 15 min. Anti-mouse HRP-linked
secondary antibody (diluted 1:7500) (Santa Cruz Biotechnol-
ogy) in blocking buffer was incubated with the membrane for
2 h at room temperature. Antibody binding was measured by
chemiluminescence and incubation of 2 ml of ECL substrate
(Pierce) for 2min. The filmwas then developed in the XOMAT
(Konica) developer.
RESULTS
Cloning and Expression of T. gondiiMIF—T. gondii encodes a
single copy of MIF that is expressed in both tachyzoite and
bradyzoite forms of the parasite (data not shown). Alignment of
TgMIF from all three strains shows 99.7% nucleotide sequence
identity and 100% identity of amino acids (data not shown).
Interspecies sequence alignments reveal that TgMIF has 59%
amino acid sequence similarity and 26% identity with mamma-
lian MIFs from host species (Fig. 1A) and 41.7% similarity with
other parasite MIFs (Fig. 1B). Amino acid numbering in this
study begins with Pro1 because the starting methionine is
cleaved. The alignments highlight the conservation of the
N-terminal Pro1, which mediates tautomerase activity, and
additional conserved residues located around the active site,
notably Lys33, Tyr96, and Ile65. This suggests that TgMIF should
have tautomerase activity. In contrast, the CXXC motif in
human MIF that is required for oxidoreductase activity is
absent in TgMIF in that the Cys59 found in humans is Ile60 in
TgMIF. In accordance with other MIF proteins, no classical
secretory signal sequence has been identified in TgMIF (25).
Successful cloning of TgMIF ORF into the expression vector
pET21a with a C-terminal His6 tag allowed recombinant
expression of the protein in E. coli and subsequent purification
using Ni2-nitrilotriacetic acid columns (Qiagen). Approxi-
mately 12 mg of protein was purified per 1 liter of culture. The
protein was used for structural analysis, biochemical analysis of
N-terminal tautomerase function, and analysis of immunolog-
ical activities.
Crystal Structure of TgMIF—Crystals formed in space group
H3(2) and x-ray diffraction data were collected at the Diamond
Light Source (Table 1). The structure ofTgMIFwas determined
FIGURE 1. Amino acid alignment of MIF sequences from T. gondii (ACY01255) and from host species (domestic cat (NC_018734. 1), human
(NP_002406), andmouse (NP_034928)) (A) andother pathogens (L.major (Q4Q413),B.malayi (AY004865),Clostridium saccharolyticum (CBK76204),
and Plasmodium falciparum (XP_001350690)) (B). Conserved residues are shown inwhite on a red background, and similar residues are highlighted in red.
Secondary structure elements for TgMIF are indicated above the alignments and for human and PlasmodiumMIF are indicated below the alignments in A and
B, respectively. TT represents a -turn.
ToxoplasmaHomologue ofMIF
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to 1.82-Å resolution. Secondary structure elements are shown
above the alignments in Fig. 1. TgMIF forms a crystallographic
trimer, and each monomer consists of a four-stranded mixed
-sheet and two -helices stacked against a -sheet (Fig. 2, A
and B). The topology of the TgMIF trimer (a ring with a central
pore, coincident with the molecular 3-fold axis) is conserved
with HsMIF as seen in superimposition images (Fig. 2C).
There are interesting differences between the TgMIF and
mammalian MIF structures. First, the short 1 turn, evident in
mammalian MIFs (Fig. 1A), is absent in the TgMIF structure.
Second, Pro15, which is conserved in mammalian MIFs and
functions as a helix “breaker” between the 1 turn and 1 helix
in HsMIF (19), is substituted with Glu16 in TgMIF. As a result,
the 1 helix in TgMIF is longer than in HsMIF, extending from
Pro13 to Leu31. Third, the central pore of the TgMIF trimer is
narrower than that of mammalian MIFs with a minimum pore
diameter of 3.5 Å at Arg61. Moreover, three sulfate ions were
bound to positively charged residues lining the pore, notably
Arg61 and Lys2, as well as a network of water molecules (Fig.
2D). The mammalian MIF pore is most often described as a
unique solvent channel; it has been proposed that its positively
charged electrostatic surface may be involved in transportation
of negatively charged ions (26) or provide a binding site for
negatively charged ligands such as dopachrome (26) or sialic
acid-containing glycolipids important in the human monocyte
response to MIF (27). However, to date, the pore has no
assigned function; and therefore, it is difficult to determine the
biological consequences of the differences in pore diameter in
TgMIF and the role of the bound sulfate ions.
TgMIF Has Tautomerase Activity but No Oxidoreductase
Activity—Mammalian MIF has been shown to catalyze tau-
tomerization reactions in which isomeric organic compounds
are readily interconverted (28). We have found TgMIF tau-
tomerase activity to be stable for 4 days following purification
(data not shown). As it has been suggested that MIFmaymedi-
ate its biological functions via enzyme activity, only freshly
purified protein was used in further biochemical and immuno-
logical assays. In a representative run, TgMIF tautomerase
activity toward substrate L-DOPAmethyl ester exhibited a spe-
cific activity of 19.3 mol/min/mg of protein, which is 104-
and117-fold lower than that of mouse (2011 mol s1 mg1;
Ref. 19) and human (2262 mol s1 mg1; this study) MIF,
respectively (Fig. 3A). TgMIF tautomerase kinetics were fully
characterized during which a Km of 9.6 mM, Vmax of 30 mol
s1 mg1, and Kcat/Km of 13.99 s1 M1 were measured (Fig.
3B). The oxidoreductase activity in TgMIF could not be
detected up to 2 h after addition of protein (data not shown).
TgMIF Tautomerase Activity Is Not Inhibited by ISO-1—
TgMIF tautomerase activity was not significantly inhibited by
preincubation with inhibitor ISO-1, reflecting observations in
other parasite MIF homologues (18, 29). HsMIF tautomerase
activity, on the other hand, was inhibited by 60% following pre-
incubation with 10 M ISO-1 (Fig. 4A).
Structural analysis reveals amino acid substitutions in the
area of the tautomerase active site that could ultimately alter
the catalytic activity of TgMIF. Mammalian MIF tautomerase
activity involves the Pro1, Lys32, and Ile64 of onemonomer in an
interactionwith Tyr95 andAsn97 (corresponding to Pro1, Lys34,
Ile65, Tyr96, and Thr98 in the TgMIF sequence) of the adjacent
monomer (30).
Most amino acids of the active site are conserved in addition
to Tyr37 and Phe114, which surround the active site. However,
replacement of Asn97 for Thr98 in the TgMIF tautomerase
active site is of importance as this substitution prevents the
formation of a hydrogen bond between MIF and the substrate
molecule, L-DOPA methyl ester (19). An identical substitution
has been reported previously in the Ancylostoma ceylanicum
MIF homologue with the suggestion that this substitution may
account for a weakened tautomerase activity (29). Further sub-
stitutions around the TgMIF tautomerase active site are
observedwherebyVal106 is replaced byTrp107, resulting in pos-
sible steric hindrance that prevents the successful binding of
ISO-1 to the active site (Fig. 4B).
Endotoxin-free TgMIF Drives IL-8 Production from Human
PBMCs and Induces ERK MAPK Activation in Bone Marrow-
derived Macrophages—LPS in recombinant TgMIF was less
than 0.008 ng/mg of protein (data not shown). TgMIF can drive
the production of IL-8 in human PBMCs in a dose-dependent
manner and is biologically active at 1 ng/ml. However, whereas
1 ng/ml HsMIF induced 22.5 ng/ml (S.E., 0.545 ng/ml) IL-8
production from PBMCs, TgMIF induced 8.0 ng/ml IL-8 (S.E.,
0.721 ng/ml). Consequently, TgMIF was40% as effective at
stimulating IL-8 as equivalent levels of HsMIF from PBMCs
(Fig. 5A).
An increase in ERK MAPK activation was observed in
murine bone marrow-derived macrophages stimulated with
TgMIF at a final concentration of 100 ng/ml. The increase in
ERKMAPK activation was represented by an increase in phos-
phorylation of p42/p44 ERK up to 30 min poststimulation, and
thereafter phosphorylation decreased. After 30-min stimula-
TABLE 1
Crystallographic data and refinement statistics
r.m.s.d., root mean square deviation.
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tion with TgMIF, there was a30-fold increase in ERKMAPK
activation compared with unstimulated control (Fig. 5B). The
same pattern of activation was observed following stimulation
of macrophages with 1 ng/ml HsMIF whereby phosphoryla-
tion peaked after 30 min of stimulation when phosphory-
lated ERK increased270-fold compared with unstimulated
cells (Fig. 5B).
DISCUSSION
Since its discovery in 1966 (31, 32), MIF has emerged as an
important and often critical mediator of the immune response
(33–35). MIF has been described as a diverse cytokine with
potent proinflammatory properties, which are potentially
mediated via its unique enzyme activities (36). However, there
are conflicting reports as to whether the tautomerase activity
can facilitate MIF biological activities (16, 37, 38). In recent
years, there have been studies describing homologues of MIF
found in many parasitic species including some helminths and
protozoa including Plasmodium, Leishmania, and Brugia spe-
cies (17–19, 39). We report herein the characterization of the
MIF homologue in the T. gondii RH strain that has 26% amino
acid sequence identity to mammalian MIFs described herein.
Production of recombinant TgMIF has facilitated structure
determination as well as characterization of its biochemical
properties and immunomodulatory capabilities.
MIF homologues from all species examined to date have
been demonstrated to catalyze the tautomerization of the sub-
strate L-DOPA methyl ester. This has been shown to be
dependent on the N-terminal proline, which is also conserved
in the TgMIF (40). Consistent with this, TgMIF exhibits meas-
urable tautomerase activity; albeit this was significantly less
than that observed for HsMIF in identical assay conditions.
TgMIF tautomerase activity is of the same order as observed
previously for Leishmania major MIF under the same assay
conditions (19). Trichinella spiralis MIF has been reported to
have tautomerase activity similar to those of TgMIF and
LmMIF (39). However, extrapolation between studies should
be done with caution because of differences in experimental
protocol.
Of note, TgMIF lacks an active oxidoreductase activity,
which is similar to other parasite MIF homologues (19). This is
likely to be caused by the absence of a second cysteine residue in
FIGURE 2. A, the x-ray crystal structures of T. gondii MIF (green) (Protein Data Bank code 4DH4) with the three sulfate ions bound in the pore shown in stick
representation. B, human MIF (Protein Data Bank code 1LJT), a representative of mammalian MIFs in schematic representation showing the trimeric ring
architecture. The ligand ISO-1 (orange) is shown in stick representation in the active site.C, overlay of themonomer structure of T. gondiiMIF (green) andhuman
MIF (blue) with secondary structure elements labeled.D, sulfate ions (yellow centered tetrahedra) and water molecules (red spheres). Amino acids in the central
pore making contacts with the sulfate ions are labeled.
ToxoplasmaHomologue ofMIF
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the CXXC motif at position 60 that is necessary for optimum
activity (41).
Analysis of the TgMIF structure reveals key differences com-
pared with mammalian MIFs (including human, cat, and
murine) around the tautomerase active site. These differences
might account for poor tautomerase activity and the subse-
quent inability of the competitive inhibitor ISO-1 to bind to this
site. There are five key amino acids in the catalytic site associ-
atedwith tautomerase activity.However, reduced catalytic abil-
ity in theTgMIF is predicted to be attributed to a substitution of
Asn97 for a Thr, which along with the steric hindrance caused
by the replacement of Val106 with Tyr prevents easy access of
the substrate/inhibitor to the active site. Notably, the MIF
homologue of A. ceylanicum is also unaffected by ISO-1. The
discriminative nature in which ISO-1 selectively binds to
HsMIF and not TgMIF (or other parasite MIFs) highlights sig-
nificant differences in the tautomerase active site that could
potentially be exploited in the development of new antiparasite
inhibitors (18, 29).
MIF has been associated with a diverse variety of biological
processes including its ability to counteract the immunosup-
pressive properties of glucocorticoids (12) and to induce angio-
genesis (42). However, a recent study (13) has highlighted the
inconsistency in reporting endotoxin removal procedures and
the presence of residual endotoxin levels present in protein
batches in MIF studies. Subsequently, the production of LPS-
free recombinant TgMIF was essential to provide reliable and
robust data; and therefore, we ensured that all protein used in
biological assays had negligible levels of residual LPS.
The initial description of MIF was as a soluble mediator
secreted by the T cells of rodents that inhibited the random
migration ofmonocytes and directed them to the site of inflam-
mation (31, 32). More recent studies have demonstrated that
MIF activates ERK pathways in both mice and humans to
induce production of the chemokine IL-8 (43, 44). Expression
of themurine homologue of IL-8,MIP-2, is similarly dependent
on activation of ERKMAPK (45), and significantly in the pres-
ent study, we have demonstrated that ERK signaling pathways
are promoted by TgMIF as well as HsMIF. IL-8 as well as its
murine homologue MIP-2 is secreted by many cells such as
endothelial and epithelial cells in response to challenge by for-
eign antigen and functionsmainly as a chemoattractant for cells
of the immune response including macrophages but primarily
neutrophils (46). HsMIF has been shown previously to induce
IL-8 production from THP-1 cells and human PBMCs (13). In
this study, we also confirmed the ability of recombinant endo-
toxin-free TgMIF to induce IL-8 production from human
PBMCs in a dose-dependent manner with TgMIF having activ-
FIGURE 3. A, TgMIF has a tautomerase activity. Recombinant protein was
expressed and purified, and TgMIF tautomerase activity was measured with
10mM L-DOPA. Recombinant HsMIF was used as a positive control. All assays
were carried out in triplicate, and data shown are means S.E. (error bars). *,
p  0.05; ***, p  0.0001. B, TgMIF tautomerase kinetics were determined
using recombinant protein and concentrations of L-DOPA ranging from 1 to
20 mM. All enzyme assays were carried out in triplicate.
FIGURE 4. A, TgMIF tautomerase activity was not affected by preincubation
with inhibitor ISO-1. HsMIF tautomerase activity was reduced by 60% fol-
lowing preincubation with ISO-1. Assays were carried out in triplicate, and
data shown are means S.E. (error bars). **, p 0.001. B, prediction of inter-
actions between active site amino acids in TgMIF (green) and HsMIF (blue)
with ISO-1 that prevent or accommodate ISO-1 inhibition, respectively.
ToxoplasmaHomologue ofMIF
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ity roughly comparable to that of HsMIF (40%). In addition,
IL-8 production has been observed in studies of other MIF
homologues; e.g. both Brugia malayi MIF homologues have
been shown to induce IL-8 production from humanmonocytes
(20). Furthermore, IL-8 production from fibroblasts and HeLa
cells has been reported from cells infected with T. gondii
tachyzoites (47). Significantly, it has been observed in the acute
stages of T. gondii infection that there is a rapid recruitment of
neutrophils to the site of infection (48), and this has been dem-
onstrated to be essential for resolution of infection. Paradoxi-
cally, the early recruitment of neutrophils to the site of infection
may also aid the spread of infection asT. gondii has been shown
FIGURE5.A, TgMIF induces IL-8production fromhumanperipheral bloodmononuclear cells in adose-dependentmanner.Data shownare fromone individual,
although the experimentwas repeatedusing samples froma further two individualswhereby the same trend in IL-8 productionwas observed. Data shownare
means of replicates for one assayS.E. (error bars).B, TgMIF activates ERKMAPKpathways in bonemarrow-derivedmacrophages in a time-dependentmanner
(panel 1). Activation peaks at 30 min poststimulation when stimulated by both TgMIF and HsMIF (panel 2). “U” indicates cells that were not stimulated
throughout the experiment. “p” indicates phosphorylated ERK isoforms. “T” indicates total phosphorylated ERK. All experiments were carried out in triplicate,
and data shown are representative of means S.E. (error bars). *, p 0.05; **, p 0.001; ***, p 0.0001.
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to trigger neutrophil synthesis of CC chemokine ligand (CCL)
3, CCL4, CCL5, and CCL20 (49). These are strongly chemotac-
tic for immature dendritic cells, subpopulations of which have
been described in recent studies as Trojan horses to facilitateT.
gondii dissemination (50, 51). Consequently, TgMIF may not
only serve to limit the severity of infection, which would be
beneficial for host survival, but also to facilitate parasite dissem-
ination to host tissue, which would promote the potential suc-
cessful completion of the parasite life cycle.
Overall, our studies demonstrate the presence of a MIF
homologue in the T. gondii genome that is enzymatically and
immunologically active in vitro. We also hypothesize a role for
this parasite protein in modulating host immune responses to
provide a favorable environment suitable for long term parasite
residence, potentially exerting these effects by interactionswith
the human MIF receptor, CD74.
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